AstraZeneca PLC (AZN)vsIncyte Corporation (INCY)
AZN
AstraZeneca PLC
$160.17
+0.33%
HEALTHCARE · Cap: $252.33B
INCY
Incyte Corporation
$121.47
-1.47%
HEALTHCARE · Cap: $25.22B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 954% more annual revenue ($61.37B vs $5.82B). INCY leads profitability with a 27.7% profit margin vs 17.0%. AZN appears more attractively valued with a PEG of 1.28. INCY earns a higher WallStSmart Score of 76/100 (B+).
AZN
Buy60
out of 100
Grade: C+
INCY
Strong Buy76
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+18.4%
Fair Value
$196.10
Current Price
$160.17
$35.93 discount
Margin of Safety
+84.0%
Fair Value
$619.23
Current Price
$121.47
$497.76 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Strong operational efficiency at 41.9%
Revenue surging 37.7% year-over-year
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Every $100 of equity generates 25 in profit
Keeps 28 of every $100 in revenue as profit
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.28 suggests the stock is reasonably priced for its growth.
Bull Case : INCY
The strongest argument for INCY centers on Operating Margin, Revenue Growth, Debt/Equity. Profitability is solid with margins at 27.7% and operating margin at 41.9%. Revenue growth of 37.7% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : INCY
The primary concerns for INCY are PEG Ratio.
Key Dynamics to Monitor
AZN profiles as a mature stock while INCY is a growth play — different risk/reward profiles.
INCY carries more volatility with a beta of 0.77 — expect wider price swings.
INCY is growing revenue faster at 37.7% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
INCY scores higher overall (76/100 vs 60/100), backed by strong 27.7% margins and 37.7% revenue growth. AZN offers better value entry with a 18.4% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Incyte Corporation
HEALTHCARE · BIOTECHNOLOGY · USA
Incyte Corp is an American pharmaceutical company based in Alapocas, Delaware.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?